REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.

RVPH | US

Overview

Corporate Details

ISIN(s):
VGG8708A1167 (+1 more)
LEI:
Country:
United States of America
Address:
10080 N WOLFE ROAD, 95014 CUPERTINO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for diseases with significant unmet medical needs. The company utilizes a chemical genomics-driven technology platform to develop treatments with improved safety and efficacy profiles. Its primary areas of focus include central nervous system (CNS), respiratory, and metabolic diseases. The company's lead drug candidate, brilaroxazine (RP5063), is in clinical development for multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, and psychosis associated with Alzheimer's and Parkinson's diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all REVIVA PHARMACEUTICALS HOLDINGS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for REVIVA PHARMACEUTICALS HOLDINGS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for REVIVA PHARMACEUTICALS HOLDINGS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Immatics N.V. Logo
Develops T-cell redirecting immunotherapies (ACT & TCR Bispecifics) for solid tumor cancers.
United States of America
IMTX
Immix Biopharma, Inc. Logo
Developing safer cell therapies for AL Amyloidosis and hematologic malignancies.
United States of America
IMMX
IMMUCELL CORP /DE/ Logo
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America
ICCC
Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America
IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea
424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America
IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan
4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America
IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America
IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America
IMVT

Talk to a Data Expert

Have a question? We'll get back to you promptly.